Skip to main content
Ambalal Sarabhai Enterprise Ltd. logo

Ambalal Sarabhai Enterprise Ltd. — Investor Relations & Filings

Ticker · AMBALALSA ISIN · INE432A01017 BSE.NS Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2026-05-24 Regulatory Filings
Country IN India
Listing BSE.NS AMBALALSA

About Ambalal Sarabhai Enterprise Ltd.

https://www.ase.life/

Ambalal Sarabhai Enterprise Ltd. is a diversified entity focused on the manufacturing and marketing of pharmaceutical products, fine chemicals, and diagnostic reagents. The organization operates through various divisions and subsidiaries, including Sarabhai Chemicals and Synbiotics Limited. Its core activities involve the production of bulk drugs, active pharmaceutical ingredients (APIs), and finished formulations across therapeutic categories such as antibiotics and vitamins. The company also provides veterinary healthcare products and specialized laboratory chemicals. Through its subsidiary Asence, it manages international marketing and distribution, targeting global healthcare markets. The enterprise maintains a focus on research-driven development to support its portfolio of medicinal products and industrial chemicals, serving both clinical and commercial sectors.

Recent filings

Filing Released Lang Actions
We hereby submit clippings of Newspaper. Kindly take the same on your records.
Regulatory Filings Classification · 85% confidence The document is a letter to the stock exchange enclosing newspaper clippings of the extract of audited financial results under SEBI Listing Regulations (Reg. 30 & 47). It is a compliance/regulatory disclosure rather than the actual financial report or AGM material. It does not contain the full results itself but notifies the exchange of their publication in the press. There is no specialized category for SEBI Reg. 30 disclosures, so it falls under the general Regulatory Filings category.
2026-05-24 English
We hereby submit details for Annual General Meeting of the Company. Kindly take the same on your records.
Interim / Quarterly Report Classification · 85% confidence The document is the detailed audited financial results (standalone & consolidated) for the quarter and year ended 31 March 2026, including full income statement, balance sheet, cash flows, notes and auditor’s report, filed pursuant to SEBI Listing Regulations. It is not a brief earnings highlight but contains comprehensive period financial statements and notes, consistent with an Interim / Quarterly Report (category IR). FY 2026
2026-05-21 English
We hereby Submit details of re-appointments as per the attached file. Kindly take the same on your records.
Interim / Quarterly Report Classification · 85% confidence The document is the outcome of a Board Meeting filed under SEBI LODR, and it contains the full audited financial results (standalone & consolidated) with detailed income statements, balance sheet, cash flows and notes for the quarter and year ended March 31, 2026. It is not merely an announcement or a short earnings press release, nor is it a full Annual Report (10-K) or proxy/solicitation material. Instead, it provides substantive financial statements for a period shorter than a full fiscal year (the quarter) alongside year-end audited results, which aligns with our definition of an Interim / Quarterly Report (IR). FY 2026
2026-05-21 English
We here by submit Financial Results (Standalone and Consolidated) for the Quarter and Year ended 31.03.2026 along with Auditors Report thereon. Kindly take the same on your records.
Interim / Quarterly Report Classification · 85% confidence The document is a Board Meeting outcome under SEBI LODR Reg. 33 that includes the full audited financial results (Standalone & Consolidated) for the quarter and year ended March 31, 2026, along with detailed P&L, balance sheet (Annexure I), notes, and auditors’ report. It is more than just an earnings highlight release and contains substantive financial statements for a quarterly period (with year-to-date figures). Thus, it is a periodic (interim/quarterly) financial report rather than a simple announcement or the full annual report. Accordingly, it fits the Interim/Quarterly Report classification. FY 2026
2026-05-21 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 85% confidence The document is the stock‐exchange filing of the Board’s meeting outcome under SEBI LODR Reg 30 & 33, whereby the Board has approved and taken on record the Audited Financial Results (Standalone & Consolidated) for the quarter and year ended March 31, 2026, accompanied by full financial statements (P&L, assets and liabilities, cash flows, segment data, notes, etc.). This is more than a brief earnings highlight and contains substantive financial data, and it relates to quarter (Q4) results, making it a comprehensive interim/quarterly report rather than just an earnings release or full annual report. Hence, it fits the definition of an Interim / Quarterly Report (IR). FY 2026
2026-05-21 English
Ambalal Sarabhai Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve Audited Financial ....
Regulatory Filings Classification · 95% confidence The document is an intimation of a Board Meeting pursuant to SEBI Listing Regulations, informing the stock exchange of the meeting date and agenda. It does not itself change board composition nor present financial results. It is a routine regulatory announcement under Indian listing rules and does not fit more specific categories. Therefore it is best classified as a general Regulatory Filing (RNS).
2026-05-14 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.